000813.SZ(000813.SZ)
000813.SZ
Dezhan Healthcare Company Limited specializes in the development and manufacturing of generic pharmaceuticals, particularly in the oncology and anti-infective segments. Its competitive position is bolstered by a robust pipeline of over 100 products, with a focus on the Chinese market and expanding international reach.
Dezhan generates revenue primarily through the sale of generic drugs, leveraging its cost-effective manufacturing capabilities and extensive distribution network in China. The company benefits from regulatory advantages in the domestic market, allowing for quicker approvals compared to international competitors.
Approval of new generic drugs in China
Changes in regulatory policies affecting drug pricing
Market share shifts in oncology and anti-infective segments
Partnerships or collaborations with international pharmaceutical companies
Regulatory changes impacting drug approval processes
Technological advancements in drug development by competitors
Increased competition from domestic and international generic manufacturers
Potential price erosion in key therapeutic areas
Negative free cash flow impacting liquidity
Dependence on a limited number of products for revenue
moderate - The healthcare sector is somewhat insulated from economic downturns, but demand for non-essential medications can decline during recessions.
low - The company has minimal debt, thus rising interest rates do not significantly impact financing costs or valuation multiples.
minimal - Dezhan's low debt-to-equity ratio (0.03) indicates limited reliance on credit markets.
value - Investors may seek undervalued opportunities given the current low price-to-book ratio.
high - The stock has shown significant price fluctuations, as evidenced by recent performance metrics.